Recombination between variants from genital tract and plasma: Evolution of multidrug-resistant HIV type 1

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1766-1774

  Kemal, Kimdar S ^a,k   Ramirez, Christina M ^b   Burger, Harold ^a,c,l   Foley, Brian ^d   Mayers, Douglas ^e   Klimkait, Thomas ^f,g   Hamy, François ^f,g,n   Anastos, Kathryn ^h   Petrovic, Katarina ^g,m   Minin, Vladimir N ⁱ   Suchard, Marc A ^b,j   Weiser, Barbara ^a,c,l  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e Idenix Pharmaceuticals Inc   (United States)

^f UNIVERSITY OF BASEL   (Switzerland)

^g InPheno AG   (Switzerland)

^h MONTEFIORE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ Fisher Bioservices   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS GENOME;

ADULT; ANTI-HIV AGENTS; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; NEVIRAPINE; PLASMA; RECOMBINATION, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; ZIDOVUDINE;

EID: 84869986611     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0383     Document Type: Article

References (25)

1. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, and Bozzette SA: The prevalence of anti-retroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
2. Hoare A, Kerr SJ, Ruxrungtham K, Law MG, Cooper DA, Phanuphak P, and Wilson DP: Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One 2010;5:e10981.
3. Malim MH and Emerman M: HIV-1 sequence variation: Drift, shift, and attenuation. Cell 2001;104:469-472.
4. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jaya-kumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, and Shafer RW: Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse tran-scriptase codon 215 revertant mutations. J Virol 2008;82:10747-10755.
5. Hu WS and Temin HM: Genetic consequences of packaging two RNA genomes in one retroviral particle: Pseudodiploi-dy and high rate of genetic recombination. Proc Natl Acad Sci USA 1990;87:1556-1560.
6. Gu Z, Gao Q, Faust EA, and Wainberg MA: Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol 1995;76 (Pt 10):2601-2605.
7. Kellam P and Larder BA: Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 1995;69:669-674.
8. Fang G, Weiser B, Kuiken C, Philpott S, Rowland-Jones S, Plummer F, Kimani J, Shi B, Kaul R, Bwayo J, Anzala O, and Burger H: Recombination following superinfection by HIV-1. AIDS 2004;18:153-159.
9. Chohan B, Lavreys L, Rainwater SM, and Overbaugh J: Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol 2005;79:10701-10708.
10. Kemal KS, Foley B, Burger H, Anastos K, Minkoff H, Kitchen C, Philpott S, Gao W, Robison E, Holman S, Dehner C, Beck S, Meyer W, Landay A, Kovacs A, Bremer J, and Weiser B: HIV-1 in genital tract and plasma of women: compartmen-talization of viral sequences co-receptor usage, and glyco-sylation. Proc Natl Acad Sci USA 2003;100:12972-12977.
11. Shi B, Kitchen C, Weiser B, Mayers D, Foley B, Kemal K, Anastos K, Suchard M, Parker M, Brunner C, and Burger H. Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy. Virology 2010;404:5-20.
12. Blick G, Kagan RM, Coakley E, Petropoulos C, Maroldo L, Greiger-Zanlungo P, Gretz S, and Garton T: The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis 2007;195:1250-1259.
13. Fang G, Zhu G, Burger H, Keithly JS, and Weiser B: Minimizing DNA recombination during long RT-PCR. J Virol Methods 1998;76:139-148.
14. Suchard MA, Weiss RE, Dorman KS, and Sinsheimer JS: Inferring spatial phylogenetic variation along nucleotide sequences: A multiple change-point model. J Am Stat Assoc 2003;98:427-431.
15. Minin VN, Dorman KS, Fang F, and Suchard MA: Dual multiple change-point model leads to more accurate recombination detection. Bioinformatics 2005;21:3034-3042.
16. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, and Ray SC: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
17. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, and Frost SD: Automated phylogenetic detection of recombination using a genetic algorithm. Mol Biol Evol 2006;23:1891-1901.
18. Suné C, Brennan L, Stover DR, and Klimkait T: Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. Clin Microbiol Infect 2004;10:119-126.
19. Lima DV, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, and Montaner JSG: Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS 2008; 22:2371-2380.
20. Graham SM, Masese L, Gitau R, Jalalian-Lechak, Richardson BA, Peshu N, Mandaliya K, Kiarie JN, Jaoko W, Ndinya-Achola J, Overbaugh J, and McClelland RS: Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 2010;202:1538-1542.
21. Nikolenko GN, Svarovskaia ES, Delviks KA, and Pathak VK: Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J Virol 2004;78:8761-8770.
22. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Bor-kow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Cas-triota G, and Prasad VR: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-1285.
23. Mee P, Fielding KL, Charalambous S, Churchyard GJ, and Grant AD: Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
24. Smith DM and Schooley RT: Running with scissors: Using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008;46:1598-1600.
25. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, and Hance AJ: Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38:37-42.